Anti‐BCAR T cells eliminate BCMA positive tumor cells more efficiently than APRIL‐based CAR T cells (19% surviving tumor cells and 19% remaining area at 18 h), however exhibited significant deficiency in killing BCMA negative tumor cells (Figure 5a,b‐ii,c–e). This evidence concerns the gene TNFRSF17 and neoplasm.